Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (HEPA) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic liver diseases through its proprietary cyclophilin inhibitor platform. This page provides investors and industry stakeholders with timely updates on material developments including clinical trial progress, regulatory milestones, and strategic partnerships.
Our curated news feed delivers essential updates on HEPA's lead candidate CRV431, a pipeline targeting fibrosis, hepatocellular carcinoma, and viral hepatitis. Users will find verified information on Phase 2/3 trial results, FDA communications, and collaborative research initiatives without promotional bias.
The repository includes press releases covering three key areas: clinical development updates detailing patient enrollment and trial outcomes, business strategy announcements regarding licensing agreements, and scientific presentations at hepatology conferences. All content is vetted for material relevance to investment analysis and therapeutic advancement.
Bookmark this page for direct access to Hepion's latest developments in pleiotropic liver disease therapies. Check regularly for updates that may influence long-term valuation assessments in the competitive hepatology therapeutics sector.
Hepion Pharmaceuticals (NASDAQ: HEPA) has announced a 1-for-50 reverse stock split, effective March 17, 2025, at 4:01 p.m. Eastern Time. The company's shares will begin trading on a split-adjusted basis on March 18, 2025, maintaining its NASDAQ symbol 'HEPA' with a new CUSIP number 426897 401.
The reverse split aims to increase the bid price to meet NASDAQ's $1.00 minimum bid requirement for continued listing. This corporate action will reduce outstanding shares from approximately 54.25 million to 1.08 million. Stockholders approved this measure at the annual meeting on March 10, 2025.
The split will automatically combine every 50 shares into one share, with fractional shares rounded up to the next whole share. This action will not affect stockholders' ownership percentages or voting power, except for minimal changes due to fractional share treatment. Proportionate adjustments will be made to stock options, incentive plans, and outstanding warrants.
Hepion Pharmaceuticals (NASDAQ:HEPA) has announced a $9.0 million public offering of 27,692,310 shares of common stock or pre-funded warrants. Each share or warrant comes with two common warrants: a series A and series B, both with an exercise price of $0.40 per share.
The combined offering price is $0.325 per common stock unit and $0.3249 for pre-funded warrant units. The proceeds will be used to repay certain debt and for general corporate purposes, including working capital, operating expenses, and capital expenditures.
The offering, managed by sole placement agent Laidlaw & Company (UK), is expected to close around January 23, 2025. The offering is made pursuant to an effective registration statement on Form S-1 and a related registration statement filed under Rule 462(b).
Hepion Pharmaceuticals (NASDAQ: HEPA) has announced the termination of its merger agreement with Pharma Two B . The merger agreement, which was initially entered into on July 19, 2024, has been mutually terminated with no termination fees required from either party. As a result, Hepion has cancelled its special stockholders meeting scheduled for December 12, 2024, and withdrawn the proposals outlined in its Definitive Proxy Statement filed with the SEC on November 8, 2024.
Hepion Pharmaceuticals (HEPA) has issued a letter to shareholders urging support for its proposed merger with Pharma Two B at the upcoming Special Meeting on December 12, 2024. The company's board unanimously recommends the merger after reviewing strategic alternatives, citing financial challenges and inability to fund clinical development. The merger would allow shareholders to participate in Pharma Two B's late-stage Parkinson's Disease treatment, P2B001. If the merger fails to receive shareholder approval, Hepion warns of potential Nasdaq delisting and bankruptcy risks due to financial resources. While Pharma Two B doesn't plan to advance Hepion's drug pipeline, Hepion remains committed to attempting to monetize its assets for shareholder benefit.
Pharma Two B and Hepion Pharmaceuticals (NASDAQ: HEPA) announced that the SEC has declared effective their merger registration statement on Form F-4. The merger, announced on July 22, 2024, will combine Pharma Two B's P2B001 Parkinson's Disease treatment candidate with Hepion's liver disease portfolio. The transaction is expected to close in Q4 2024, subject to stockholder approvals and other conditions. A special stockholder meeting is scheduled for December 12, 2024, at 9:00 AM ET via webcast. Upon closing, the combined entity will operate as Pharma Two B and trade under the symbol 'PHTB'.
Pharma Two B and Hepion Pharmaceuticals (Nasdaq: HEPA) have filed a registration statement on Form F-4 with the SEC for their proposed merger. The filing contains a proxy statement/prospectus detailing the transaction announced on July 22, 2024. Pharma Two B, developing P2B001 for Parkinson's Disease, aims to go public on Nasdaq through this merger with Hepion, which has been developing treatments for liver diseases including NASH and HCC.
The merger, approved by both companies' boards, is expected to close in Q4 2024, subject to stockholder and regulatory approvals. Post-merger, the combined entity will operate as Pharma Two B and trade under the ticker symbol "PHTB". The transaction is supported by financial advisors A.G.P./Alliance Global Partners for Hepion and Laidlaw & Company (UK) for Pharma Two B, along with respective legal advisors.
Pharma Two B, a late-stage clinical company developing P2B001 for Parkinson's Disease, has announced plans to go public through a merger with Hepion Pharmaceuticals (Nasdaq: HEPA). The deal includes a concurrent $11.5 million private placement. Post-merger, Pharma Two B shareholders will own approximately 44.5% of the combined company, Hepion shareholders 7.8%, and new investors 47.7%. The company plans to submit an NDA for P2B001 in the first half of 2026. Hepion has also secured a $2.9 million Senior Unsecured Note from institutional investors. The merger is expected to close in Q4 2024, subject to regulatory and shareholder approvals.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
